02.07.23
ADM (NYSE: ADM) has opened a new production facility in Valencia, Spain to help meet growing demand for probiotics, postbiotics, and other products that support health and wellbeing.
The production facility represents an investment north of $30 million and a more than five-fold increase in ADM’s production capacity, which will reach 50 metric tons per year. The facility will allow ADM to supply growing markets for probiotics and postbiotics in the U.S., Asia-Pacific and Europe.
The company said it expects its customer base will more than triple over the next five years as more people recognize the links between the gut microbiome and a range of health areas.
Market research from Euromonitor has predicted the probiotic supplements retail market could surge to $10.4 billion by 2027 from about $8.3 billion in 2022. That growth is being driven by rising demand for science-based probiotic formulas that are used in dietary supplements, and also dairy products, food, healthy snacks and beverages, as well as pet and animal well-being products.
ADM said the facility is the world’s first to produce both probiotics and postbiotics at the same site, and will help the company fulfill its expansion strategy in the health and wellbeing sector.
“Health and wellbeing is one of the three enduring trends powering ADM’s growth strategy: Consumers are increasingly aware of the role their gut microbiome can play in their everyday lives, and they’re seeking nutrition solutions that are backed up by science-based research,” said Mark Lotsch, president, Global Health & Wellness. “ADM is a leader in meeting this growing global demand, and we’re continuing to invest in the cutting edge of health and nutrition.”
The site will produce ADM’s probiotic BPL1 and the heat-treated BPL1 postbiotic, as well as other ADM proprietary strains. It will also be able to support further growth in ADM’s Bio-Kult brand of products in the U.K.
The new facility is located close to ADM’s research and development center in the University of Valencia Scientific Park, where ADM scientists undertake activity including next-generation genome sequencing and early-stage testing of new bacterial strains.
The production facility represents an investment north of $30 million and a more than five-fold increase in ADM’s production capacity, which will reach 50 metric tons per year. The facility will allow ADM to supply growing markets for probiotics and postbiotics in the U.S., Asia-Pacific and Europe.
The company said it expects its customer base will more than triple over the next five years as more people recognize the links between the gut microbiome and a range of health areas.
Market research from Euromonitor has predicted the probiotic supplements retail market could surge to $10.4 billion by 2027 from about $8.3 billion in 2022. That growth is being driven by rising demand for science-based probiotic formulas that are used in dietary supplements, and also dairy products, food, healthy snacks and beverages, as well as pet and animal well-being products.
ADM said the facility is the world’s first to produce both probiotics and postbiotics at the same site, and will help the company fulfill its expansion strategy in the health and wellbeing sector.
Realizing Growth in Health and Wellness
ADM aims to increase health and wellness revenue from over $500 million in 2022 to $2 billion within 10 years.“Health and wellbeing is one of the three enduring trends powering ADM’s growth strategy: Consumers are increasingly aware of the role their gut microbiome can play in their everyday lives, and they’re seeking nutrition solutions that are backed up by science-based research,” said Mark Lotsch, president, Global Health & Wellness. “ADM is a leader in meeting this growing global demand, and we’re continuing to invest in the cutting edge of health and nutrition.”
The site will produce ADM’s probiotic BPL1 and the heat-treated BPL1 postbiotic, as well as other ADM proprietary strains. It will also be able to support further growth in ADM’s Bio-Kult brand of products in the U.K.
The new facility is located close to ADM’s research and development center in the University of Valencia Scientific Park, where ADM scientists undertake activity including next-generation genome sequencing and early-stage testing of new bacterial strains.
